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Abstract
Objective: To test the association between coffee consumption and risk of
all-cause, CVD and cancer death in a European cohort.
Design: Prospective cohort study. Cox proportional hazards models with
adjustment for potential confounders to estimate multivariable hazard ratios
(HR) and 95% CI were used.
Setting: Czech Republic, Russia and Poland.
Subjects: A total of 28 561 individuals followed for 6·1 years.
Results: A total of 2121 deaths (43·1% CVD and 35·7% cancer mortality) occurred
during the follow-up. Consumption of 3–4 cups coffee/d was associated with lower
mortality risk in men (HR= 0·83; 95% CI 0·71, 0·99) and women (HR= 0·63; 95% CI
0·47, 0·84), while further intake showed non-signiﬁcant reduced risk estimates
(HR= 0·71; 95% CI 0·49, 1·04 and HR= 0·51; 95% CI 0·24, 1·10 in men and women,
respectively). Decreased risk of CVD mortality was also found in men (HR= 0·71;
95% CI 0·54, 0·93) for consumption of 3–4 cups coffee/d. Stratiﬁed analysis revealed
that consumption of a similar amount of coffee was associated with decreased risk
of all-cause (HR= 0·61; 95% CI 0·43, 0·87) and cancer mortality (HR= 0·59; 95% CI
0·35, 0·99) in non-smoking women and decreased risk of all-cause mortality for
>4 cups coffee/d in men with no/moderate alcohol intake.
Conclusions: Coffee consumption was associated with decreased risk of mortality.
The protective effect was even stronger when stratiﬁcation by smoking status and
alcohol intake was performed.
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Coffee is among the most consumed non-alcoholic
beverages worldwide(1). Besides the gastronomic
aspects, coffee has been suggested to affect human health
and disease(2). Although in the past it has been considered
unhealthful due to its association with some negative
outcomes following acute ingestion (i.e. rise in blood
pressure and plasma lipids, inhibition of insulin activity),
adverse health outcomes of long-term coffee consumption
have not been found. Indeed, several epidemiological
studies have explored the relationship between
coffee intake and cardiovascular risk factors(3,4), CVD(5)
and certain types of cancer(6), suggesting that a protective
effect may exist. From an epidemiological point of
view, long-term coffee drinking exerts different effects
from acute intake typically examined under experimental
conditions. Long-term experimental studies have
demonstrated that habitual coffee drinkers develop
tolerance to the acute effects of caffeine and may experi-
ence the effects of other coffee compounds that are related
with its beneﬁcial role on human health(7). Coffee is a
complex mixture of several biochemically active compo-
nents, including caffeine, phenolic compounds and
minerals (magnesium and potassium). Many of these
compounds may act as antioxidants, thus preventing
the state of subclinical inﬂammation involved in the
pathogenesis of diseases such as cancer and CVD(8).
Among them, chlorogenic acids are responsible for
ameliorating hypertension, glucose and lipid metabolism,
whereas diterpenes demonstrate anti-carcinogenic
properties(9).
Recently published prospective studies evaluating the
association between coffee consumption and mortality in
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large European cohorts have been mostly conducted
in Northern(10–12) and Western European countries(13).
Findings obtained are puzzling and inconsistent,
suggesting that signiﬁcant differences between countries
and methods of coffee consumption may be relevant for
the outcome explored. We recently reported an inverse
association between coffee consumption and metabolic
impairment and decreased risk of developing hyperten-
sion in Polish individuals free of diseases at baseline(14,15).
However, whether these associations may be translated
into a decreased risk of mortality following a prospective
evaluation is unknown. To date, no further data from
Eastern European countries are available. The aim of the
present study was to test the association between coffee
consumption and risk of all-cause, CVD and cancer
mortality in the HAPIEE (Health, Alcohol and Psychosocial
factors In Eastern Europe) study, a large-scale cohort study
including adult individuals from the Czech Republic,
Russia and Poland.
Methods
Study population
The HAPIEE study is a multicentre prospective cohort
study investigating the role of biological, dietary, lifestyle
and environmental factors in cardiovascular and other
chronic diseases(16). The criteria for sample selection
and the methods are reported in detail elsewhere(16).
Brieﬂy, a random sample of 28 945 individuals (aged 45–
69 years) was recruited at the baseline survey conducted
in 2002–2005 (response ratio of 59%) in Novosibirsk
(Russia), Krakow (Poland) and six Czech urban
centres. The participants, after providing written informed
consent, ﬁlled in a structured questionnaire and were
invited to a clinical examination. Participants who left
more than 50% of food items blank in the FFQ or reported
implausible energy (energy intake <2092/>16 736 kJ/d
(<500/>4000 kcal/d) for females and <3347/>20 920 kJ/d
(<800/>5000 kcal/d) for males, n 384) were excluded
from the analyses. A total of 28 561 individuals were
included for the ﬁnal analysis. The study was conducted
according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects
were approved by the University College London Hospital
research ethics committee and by ethical committees in
each participating country. Written informed consent was
obtained from all subjects.
Demographic, lifestyle and clinical measurements
Sociodemographic and lifestyle characteristics included
age, gender, educational and occupational level, smoking
and alcohol drinking habits. Physical activity included
energy expenditure both at work and leisure time. The
overall amount of energy expenditure was calculated and
categorized as low, moderate and high activity level.
Individuals were categorized according their smoking
status as non-smoker and current smoker. Alcohol
consumption was categorized as none or low (≤12 g/d)
and moderate to high alcohol drinker (>12 g/d). The
physical examination included measurement of height,
weight and blood pressure using standard procedures(16).
BMI was calculated according the formula [weight (kg)]/
[height (m)]2. Blood pressure was measured three times at
the end of the physical examination and the ﬁnal value
was the mean among the three measurements. Participants
were categorized as having hypertension at baseline if
they had a systolic and/or a diastolic blood pressure
measurement higher than 139 and/or 89mmHg,
respectively, or had taken hypertensive medication within
the last 2 weeks. Participants were categorized as having
diabetes at baseline if they had fasting plasma glucose
>120mg/dl, previously diagnosed type 2 diabetes or
were receiving treatment for diabetes. Participants were
categorized as having hypercholesterolaemia if they were
previously diagnosed with or using a speciﬁc treatment for
this lipid abnormality. Presence of CVD or cancer relied
on previous diagnosis. Participants were ﬁnally asked
whether they also had family history of CVD or cancer.
Dietary assessment
Dietary data were collected by using an FFQ based on the
tool developed by Willett et al.(17) and subsequently
adapted in the Whitehall II Study(18). The Czech, Russian
and Polish FFQ consisted of 136, 147 and 148 food and
drink items, respectively (the different numbers of
questions are due to country-speciﬁc dishes). An instruction
manual, which included photographs to facilitate the
estimation of portion sizes, was used. Participants were
asked how often, on average, they had consumed that
amount of the item during the last 3 months, with
nine responses ranging from ‘never or less than once
per month’ to ‘six or more times per day’. Moreover,
participants were asked to include additional foods and
frequency of consumption by manual entry.
The average beverage consumption was calculated
(in millilitres) by following the standard portion sizes used
in the study and then converted into 24 h intake.
We categorized daily coffee consumption according to
standard cups of coffee (150ml) as: (i) <1 cup/d;
(ii) 1–2 cups/d; (iii) 3–4 cups/d; and (iv) >4 cups/d.
Mortality
The mortality status of participants was obtained through
linkage with mortality registers of their respective country.
Speciﬁcally, mortality data in Russia were obtained from
the death register developed by the Institute of Internal
Medicine, based on data from medical death certiﬁcates,
the Novosibirsk ofﬁce of the State Statistical Bureau and
the population registration bureau. In Poland, data from
the Local Register of Residents of the City of Krakow and
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Central Statistical Ofﬁce were used. In the Czech Republic,
data from the National Death Register were used. The
follow-up period was until December 2011 for the Czech
Republic or December 2010 for Russia and Poland.
Participants who were lost to follow-up were censored at
their last date of contact (n 527). The underlying cause
of death was assigned according to the International
Classiﬁcation of Diseases, 10th Revision (ICD-10). The
primary end point in the current analysis was death from
any cause. We also conducted analyses according to CVD
(ICD-10 codes I00–I99, CHD codes I20–I25, stroke codes
I60–I69) and cancer mortality (codes C00–D48).
Statistical analysis
The distribution of background characteristics was
compared between different coffee consumption groups
using ANOVA or the Mantel–Haenszel test. We calculated
person-years of follow-up for each participant from the date of
the baseline questionnaire to the date of death from any
cause, loss to follow-up or end of the follow-up period,
whichever came ﬁrst. Hazard ratios (HR) and 95% CI for the
association between coffee consumption and all end points,
using the lowest category as the reference, were calculated by
Cox proportional hazards models. No interactions between
countries and categories of coffee consumption were
detected, so we calculated the results of the Cox regression in
the pooled sample and checked possible differences in an
additional analysis by country cohorts. A crude model was
adjusted for age (continuous) and gender. A multivariate
model was built adjusting for country (Poland, Czech
Republic, Russia), educational level (low, medium, high),
physical activity (low, medium, high), smoking status
(yes/no), history of CVD or cancer (yes/no), health status
(presence of hypertension, diabetes, use of cholesterol-
lowering medications), family history of CVD (yes/no),
family history of cancer (yes/no), menopausal status in
women (yes/no), alcohol intake >12g/d (yes/no), total
energy intake (continuous), SFA intake (continuous), PUFA
intake (continuous), n-3 PUFA intake (continuous) and use of
vitamin supplements (yes/no). The analysis was performed
also for CVD and cancer mortality and stratiﬁed by gender
and smoking status. To evaluate reverse causation, the risk of
mortality excluding deaths occurring in the ﬁrst 2 years from
baseline, in individuals with a past history of CVD or cancer,
and after sequential exclusion of individuals with CVD risk
factors (hypertension, diabetes, use of cholesterol-lowering
medications), was also estimated. All reported P values were
based on two-sided tests and compared with a signiﬁcance
level of 5%. Analyses were performed using the statistical
software package SPSS Statistics Version 17.0.
Results
A total of 2121 deaths (1435 men and 686 women)
occurred during a mean follow-up of 6·1 years. Of these
deaths, 913 (43·1%) were due to CVD and 755 (35·7%)
were due to cancer mortality. Distribution of background
characteristics by categories of coffee consumption did not
differ signiﬁcantly between men and women (Table 1).
No speciﬁc trends were identiﬁed, with the exception of
the distribution of current smokers (increasing with
increased category of coffee consumption) and prevalence
of hypertension and CVD (decreasing with increased
category of coffee consumption). High alcohol intake was
more frequent among men than women (about 18–20% v.
1–4%, respectively) and associated with higher coffee
consumption, whereas prevalence of hypercholester-
olaemia and family history of CVD and cancer were higher
in women than in men.
Frequency and risk of all-cause, CVD and cancer
mortality based on coffee consumption are shown in
Table 2. Risk of all-cause mortality decreased with
increasing coffee consumption in both men and women,
both in age-adjusted and multivariate-adjusted models,
with no signiﬁcant difference in the distribution of deaths
across categories of exposure between genders (P= 0·094;
Table 2). A signiﬁcant risk reduction of 17% (HR= 0·83;
95% CI 0·71, 0·99) in men and 37% (HR= 0·63; 95% CI
0·47, 0·84) in women was found for consumption of 3–4
cups/d, whereas further intake led to a non-signiﬁcant
decrease in risk. The risk estimate of all-cause mortality by
category of coffee consumption partially reﬂected the risk
of mortality by CVD in both women and men, whereas
non-signiﬁcant decreased risk in women and non-
signiﬁcant increased in men for risk cancer mortality was
found. The stratiﬁed analysis by country revealed
consistent non-signiﬁcant decreasing mortality risk
estimates with increasing coffee consumption across all
cohorts and signiﬁcant decreased risk up to 4 cups/d or
less (see online supplementary material, Supplemental
Table 1). Moreover, the analysis revealed that the Russian
cohort was the only one showing an increased non-
signiﬁcant risk of death by cancer, whereas the others
showed a decreased, non-signiﬁcant risk.
A number of analyses to evaluate possible reverse
causation are reported in the online supplementary
material, Supplemental Table 2. Analysis performed by
excluding deaths occurring within the ﬁrst 2 years from
baseline of follow-up showed no signiﬁcant alteration of
the results among both men and women. No substantially
different risks were estimated when excluding individuals
with a past history of CVD or cancer. Sequential exclusion
also of individuals with any CVD risk factors weakened
CVD mortality risk in women due to the limited cases in
the highest categories of exposure, whereas it led to a
non-signiﬁcant decreased risk of death from cancer in men
consumers of 3–4 cups coffee/d.
Results of stratiﬁed analyses by smoking status
and alcohol intake are presented in Tables 3 and 4,
respectively. Distribution of deaths across categories of
exposure between smokers and non-smokers was
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Table 1 Baseline characteristics by coffee consumption in 28 561 men and women living in the Czech Republic, Poland and Russia in 2002–2005; the HAPIEE (Health, Alcohol and Psychosocial factors In
Eastern Europe) study
Coffee consumption, men Coffee consumption, women
<1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d <1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d
n or
Mean
% or
SD
n or
Mean
% or
SD
n or
Mean
% or
SD
n or
Mean
% or
SD P
n or
Mean
% or
SD
n or
Mean
% or
SD
n or
Mean
% or
SD
n or
Mean
% or
SD P
No. of participants 5431 – 4102 – 3360 – 457 – – 5386 – 5505 – 3896 – 332 – –
Age (years), mean and SD 58·7 7·1 58·7 6·9 57·1 7·0 55·1 6·3 <0·001 59·0 7·0 58·1 7·0 55·7 6·7 54·5 7·1 <0·001
BMI (kg/m2), mean and SD 27·5 4·3 27·8 4·1 27·4 4·1 26·3 4·2 <0·001 29·7 5·6 28·9 5·2 28·0 5·1 27·8 5·3 <0·001
Current smoker, n and % 1696 31·2 1480 36·1 1632 48·6 331 72·4 <0·001 509 9·5 1085 19·8 1364 35·3 170 51·8 <0·001
Low educational level, n and % 2078 38·2 1728 42·1 1356 40·2 152 33·1 <0·001 2126 39·5 21·69 39·5 1448 37·3 132 39·8 0·026
Low physical activity level, n and % 2576 48·4 1548 39·0 1279 39·0 243 54·2 <0·001 2966 56·3 2173 40·9 1315 35·0 164 50·8 <0·001
Alcohol intake (>12g/d), n and % 1007 18·5 752 18·3 760 22·5 95 20·7 <0·001 65 1·2 116 2·1 146 3·7 14 4·2 <0·001
Health status
Hypertension, n and % 3114 57·3 2087 50·7 1449 43·0 145 31·7 <0·001 3663 68·0 3023 55·1 1547 39·8 117 35·3 <0·001
Diabetes, n and % 537 9·9 505 12·3 320 9·5 24 5·2 <0·001 505 9·4 533 9·7 269 6·9 15 4·5 <0·001
Hypercholesterolaemia, n and % 1325 24·4 1269 30·9 968 28·7 72 15·7 <0·001 1665 30·9 2008 36·6 1189 30·7 76 23·2 <0·001
CVD, n and % 1308 24·3 891 22·1 541 16·3 69 15·2 <0·001 1281 24·0 882 16·4 383 10·1 34 10·6 <0·001
Cancer, n and % 168 3·1 106 2·6 106 3·2 11 2·4 0·363 280 5·2 331 6·1 253 6·7 19 5·8 0·037
Family history of CVD, n and % 2373 45·6 1652 42·6 1273 40·3 204 46·5 <0·001 3320 63·8 3430 66·7 2460 68·8 206 66·5 <0·001
Family history of cancer, n and % 1412 26·7 1152 29·0 1050 32·3 122 27·1 <0·001 1594 30·1 1922 36·3 1491 39·9 132 41·0 <0·001
Dietary factors
Vitamin supplement use, n and % 959 17·7 690 16·8 542 16·1 75 16·3 0·267 946 17·6 1078 19·7 786 20·3 57 17·3 0·005
Total energy intake (kJ/d), mean
and SD
10155 4197 9862 4109 9983 4109 11724 6941 <0·001 9046 3347 8924 3993 8941 3498 11 251 10519 <0·001
Total energy intake (kcal/d), mean
and SD
2427 1003 2357 982 2386 982 2802 1659 <0·001 2162 800 2133 787 2137 836 2689 2514 <0·001
SFA intake (g/d), mean and SD 38·8 21·3 38·2 17·9 38·9 20·8 48·2 38·6 <0·001 33·4 15·9 33·7 15·5 33·4 16·4 46·1 51·5 <0·001
PUFA intake (g/d), mean and SD 18·7 10·8 16·5 9·1 16·9 9·7 21·6 16·3 <0·001 18·5 10·2 15·7 8·9 15·6 9·2 22·1 21·0 <0·001
n-3 PUFA intake (g/d), mean and SD 1·3 0·8 1·1 0·7 1·1 0·7 1·4 1·1 <0·001 1·3 0·8 1·1 0·7 1·1 0·7 1·4 1·1 <0·001
http://dx.doi.org/10.1017/S1368980016001749
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signiﬁcantly different, with more numerous mortality cases
among the categories of higher coffee intake in smokers
than in non-smokers (P< 0·001). Nevertheless, consump-
tion of 3–4 cups coffee/d was associated with signiﬁcantly
decreased risk of CVD mortality in smoker men (HR=
0·66; 95% CI 0·47, 0·93) and decreased risk of all-cause
(HR= 0·61; 95% CI 0·43, 0·87) and cancer mortality
(HR= 0·59; 95% CI 0·35, 0·99) in non-smoker women
(Table 3). Results were mainly conﬁrmed after strati-
ﬁcation by alcohol consumption, with no signiﬁcant dif-
ference between groups (P= 0·068; Table 4). However,
among men with alcohol intake of ≤12 g/d, consumption
of >4 cups coffee/d was associated with a decreased risk
of all-cause mortality (HR= 0·61; 95% CI 0·39, 0·94).
Discussion
In the present study we found that daily coffee consumption
was signiﬁcantly correlated with decreased risk of
all-cause and CVD death, but the effect was not observed
when drinking more than 4 cups/d. Interestingly, we also
found that after stratifying the sample by smoking status,
coffee consumption was inversely associated with risk of
death by cancer in women drinking 3–4 cups coffee/d. Lack
of decreased risk of death for higher intakes of coffee has
been recently reported, suggesting that the association of
coffee drinking with mortality risk may not be linear(19).
These ﬁndings are in line with a recent dose–response meta-
analysis(20). It has been hypothesized that intake of high
quantities of coffee may have an acute effect at the vascular
level by triggering coronary events and, consequently,
increasing the risk of myocardial infarction in speciﬁc patient
groups, such as the elderly and those at high CVD risk(21,22).
This may depend on the biological effect of caffeine intake
that causes an acute increase in arterial wave reﬂection,
which in turn increases the pulsatile load of the heart.
Furthermore, it has been reported that excessive intakes
may also aggravate cardiac arrhythmias and raise plasma
homocysteine(23). However, other studies have reported that
habitual coffee consumption is not directly associated with
myocardial infarction in the general population and that
the effects of caffeine in habitual coffee drinkers are atte-
nuated or overall absent due to the development of
tolerance(7,24–27). The contrasting hypotheses on the effects
of caffeine on cardiovascular events may reﬂect the modality
of coffee consumption. Indeed, a habitual, rather than
occasional intake of coffee may lead to desensitization to the
acute effects of caffeine but excessive intake (i.e. more than
4 cups/d) could exacerbate its harmful effects.
The analysis of cancer mortality according coffee
consumption revealed non-signiﬁcant associations towards
both increased and decreased risk, but after stratifying the
analysis by smoking status, consumption of 3–4 cups coffee/d
was associated with a decreased risk of death from
cancer of about 40% compared with non-drinkers. Some
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Public Health Nutrition
Table 3 Stratified analysis by smoking status of age- and multivariate-adjusted hazard ratios (HR) and 95 % confidence intervals for all-cause, CVD and cancer mortality by coffee consumption in
men and women living in the Czech Republic, Poland, and Russia over a period of 6 years; the HAPIEE (Health, Alcohol and Psychosocial factors In Eastern Europe) study
Coffee consumption, men Coffee consumption, women
<1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d <1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d
Ref. HR 95 % CI HR 95 % CI HR 95 % CI Ref. HR 95 % CI HR 95 % CI HR 95 % CI
Smokers
Death from all causes
Person-years 9604 8348 – 9782 – 2003 – 2861 6245 – 8689 – 1146 –
No. of deaths 293 209 – 178 – 33 – 48 63 – 58 – 8 –
Multivariate-adjusted* 1 1·06 0·87, 1·29 0·82 0·65, 1·02 0·79 0·53, 1·19 1 0·72 0·44, 1·16 0·61 0·37, 1·02 0·51 0·19, 1·33
Death from CVD
No. of deaths 147 82 – 63 – 13 – 14 27 – 18 – 4 –
Multivariate-adjusted* 1 0·87 0·65, 1·18 0·66 0·47, 0·93 0·76 0·42, 1·39 1 1·63 0·66, 4·01 1·49 0·58, 3·80 0·97 0·19, 4·82
Death from cancer
No. of deaths 70 67 – 81 – 15 – 12 25 – 35 – 3 –
Multivariate-adjusted* 1 1·45 0·99, 2·11 1·37 0·93, 2·02 1·24 0·61, 2·55 1 0·87 0·39, 1·92 0·76 0·34, 1·71 0·62 0·13, 2·93
Non-smokers
Death from all causes
Person-years 21962 15652 – 11120 – 833 – 30100 27158 – 16 927 – 995 –
No. of deaths 378 209 – 122 – 3 – 270 164 – 65 – 3 –
Multivariate-adjusted* 1 0·89 0·72, 1·09 0·89 0·68, 1·14 0·42 0·14, 1·32 1 0·76 0·59, 0·97 0·61 0·43, 0·87 0·47 0·12, 1·92
Death from CVD
No. of deaths 187 91 – 49 – 1 – 134 58 – 22 – 0 –
Multivariate-adjusted* 1 0·92 0·68, 1·25 0·79 0·52, 1·21 0·33 0·05, 2·36 1 0·58 0·38, 0·87 0·70 0·39, 1·25 0·00 0·00, 0·00
Death from cancer
No. of deaths 113 82 – 51 – 0 – 92 70 – 32 – 3 –
Multivariate-adjusted* 1 0·98 0·69, 1·39 1·11 0·74, 1·66 0·00 0·00, 0·00 1 0·85 0·59, 1·23 0·59 0·35, 0·99 1·09 0·27, 4·53
Ref., reference category.
*Adjusted for age (continuous), gender, smoking status (yes/no), BMI (continuous), educational level (low, medium, high), physical activity (low, medium, high), alcohol intake (>12 g/d), hypertension, diabetes,
hypercholesterolaemia, history of CVD or cancer, family history of CVD, family history of cancer, total energy intake (continuous), vitamin supplement use, SFA, PUFA and n-3 PUFA intake (continuous), and menopausal
status (in women).
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Table 4 Stratified analysis by alcohol intake of multivariate-adjusted hazard ratios (HR) and 95 % confidence intervals for all-cause, CVD and cancer mortality by coffee consumption in men and
women living in the Czech Republic, Poland, and Russia over a period of 6 years; the HAPIEE (Health, Alcohol and Psychosocial factors In Eastern Europe) study
Coffee consumption, men Coffee consumption, women
<1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d <1 cup/d 1–2 cups/d 3–4 cups/d >4 cups/d
Ref. HR 95 % CI HR 95 % CI HR 95 % CI Ref. HR 95 % CI HR 95 % CI HR 95 % CI
Alcohol intake >12 g/d
Death from all causes
Person-years 6357 4916 – 5293 – 602 – 404 771 – 1104 – 107 –
No. of deaths 117 80 – 68 – 9 – 8 4 – 6 – 0 –
Multivariate-adjusted 1 0·96 0·70, 1·33 0·70 0·49, 0·99 0·75 0·35, 1·63 1 0·22 0·04, 1·17 0·10 0·02, 0·51 NA NA
Death from CVD
No. of deaths 50 26 – 17 – 4 – 3 0 – 2 – 0 –
Multivariate-adjusted* 1 0·69 0·41, 1·17 0·35 0·18, 0·69 0·75 0·23, 2·45 NA NA NA NA NA NA NA
Death from cancer
No. of deaths 28 29 – 35 – 5 – 2 2 – 4 – 0 –
Multivariate-adjusted* 1 1·54 0·86, 2·76 1·66 0·93, 2·97 2·07 0·70, 6·10 NA NA NA NA NA NA NA
Alcohol intake ≤12 g/d
Death from all causes
Person-years 25328 19199 – 15771 – 2253 – 32628 32797 – 24 725 – 2060 –
No. of deaths 556 340 – 235 – 27 – 311 226 – 119 – 11 –
Multivariate-adjusted* 1 0·88 0·75, 1·03 0·74 0·62, 0·89 0·61 0·39, 0·94 1 0·73 0·59, 0·90 0·58 0·44, 0·76 0·50 0·23, 1·08
Death from CVD
No. of deaths 285 147 – 95 – 10 – 145 86 – 39 – 4 –
Multivariate-adjusted* 1 0·78 0·67, 0·98 0·61 0·46, 0·81 0·57 0·30, 1·10 1 0·56 0·40, 0·80 0·60 0·39, 0·93 0·38 0·09, 1·60
Death from cancer
No. of deaths 156 122 – 97 – 10 – 102 93 – 64 – 6 –
Multivariate-adjusted* 1 1·09 0·83, 1·44 1·10 0·81, 1·49 0·55 0·22, 1·36 1 0·94 0·68, 1·30 0·71 0·47, 1·07 0·76 0·27, 2·12
Ref., reference category; NA, not applicable.
*Adjusted for age (continuous), gender, smoking status (yes/no), BMI (continuous), educational level (low, medium, high), physical activity (low, medium, high), smoking status (yes/no), hypertension, diabetes,
hypercholesterolaemia, history of CVD or cancer, family history of CVD, family history of cancer, total energy intake (continuous), vitamin supplement use, SFA, PUFA and n-3 PUFA intake (continuous) and menopausal
status (in women).
C
o
ffee
in
take
an
d
m
o
rtality
in
E
ast
E
u
ro
p
e
7
http://dx.doi.org/10.1017/S1368980016001749
D
ow
nloaded from
 http:/w
w
w
.cam
bridge.org/core. U
niversity C
ollege London, on 24 O
ct 2016 at 10:13:59, subject to the C
am
bridge C
ore term
s of use, available at http:/w
w
w
.cam
bridge.org/core/term
s.
other cohort studies speciﬁcally explored the association
between coffee consumption and cancer mortality, reporting
a decreased mortality risk from cancer(28). Moreover, recent
meta-analyses including epidemiological studies showed
a protective effect of coffee consumption against liver,
colorectal, breast and prostate cancer incidence(6). Coffee has
been hypothesized to play a role in the early phases
of cancer development and promotion, delaying disease
progression and thus prolonging a person’s lifespan. As we
found a signiﬁcant association between coffee consumption
and cancer mortality only in non-smoker women, we
may hypothesize that smoking status might be a strong
confounding factor and that the potentially beneﬁcial effects
of coffee are appreciable only when analysis is restricted to
individuals free of the confounding effect of smoking.
Another hypothesis is that the harmful effects of smoking
among smokers counteract the potentially protective effect of
coffee. However, some questions remain, for instance the
lack of an evident decreased risk among non-smoker men.
Knowledge of the type of cancer could help to draw
more accurate hypotheses and explanations, but the data
presented in the current study lack this information and future
studies should take into account our results to better design
their analyses.
The polyphenol content of coffee represents the main
biological explanation for its beneﬁts on health. During
recent years, dietary patterns rich in polyphenols, such as
the Mediterranean diet, have been suggested to exert
their beneﬁts due to their polyphenol content that may
contribute towards their protective effects against diseases
with an inﬂammatory basis(29). Coffee has lately been
demonstrated to be among the main contributors to
polyphenol content in the diet of individuals living in
Eastern European countries(30–34) as well as among the
foods with the highest antioxidant capacity(35). Among
the most important, chlorogenic acids are molecules which
belong to the group of hydroxycinnamic acids demonstrat-
ing the ability to affect some metabolic pathways, for
instance by improving glucose metabolism and decreasing
inﬂammation and endothelial dysfunction(36). This family of
molecules has also demonstrated anti-tumour properties by
inhibiting key enzymes involved in tumour genesis and
metastasis(37). Other components, such as the diterpenes
kahweol and cafestol, may play a role in the regulation of
angiogenesis, apoptosis and inﬂammation processes and
have been proposed as possible anti-tumour agents(38,39).
Together with these effects, an excess of the same
compounds, for instance caffeine and diterpenes, may
produce harmful effects, such as an acute rise in blood
pressure, increase in serum cholesterol and homocysteine
levels, and decreased insulin sensitivity, all contributing to
raise the risk for CVD(23,40,41). The equilibrium between
positive and negative effects on health may explain the
ﬁndings of our and other studies, as an excessive
consumption was not associated with the same beneﬁts as
moderate daily intake. The antioxidant compounds are
thought to counteract the potentially harmful effects of
caffeine or diterpenes, but an excessive intake of the latter
may disrupt such balance, thus weakening or even
annulling the overall beneﬁcial effect of coffee. Moreover,
other factors may impact the effects of coffee consumption
on health. For instance, some previous studies have
emphasized the possible role of associated lifestyle habits,
such as smoking status, which largely correlates with
mortality. Also in the present study we conﬁrmed that
current smoking, associated with coffee drinking, was
weakening the effect of coffee on CVD mortality, as a
stronger association between coffee and CVD mortality was
found among non-smokers. In light also of the aforemen-
tioned ﬁndings obtained on cancer mortality, an accurate
study of smoking status and coffee drinking should be
conducted in future investigations aimed to explain the
effects of coffee on human health, whatever is the outcome.
It is still debatable if the health status of a person may
inﬂuence coffee consumption (i.e. those with poorer health
conditions drinking less coffee), thus biasing the results.
Generally, studies on coffee consumption and mortality
report analyses with the exclusion of deaths occurring within
the ﬁrst 2 years from baseline observation with no substantial
changing of the results. In our study we performed a similar
analysis and the results suggested that health status at base-
line did not necessarily explain the aforementioned asso-
ciation. In addition, we also took into account health status
by adjusting for a previous history of CVD and cancer, as
well as the presence of CVD risk factors, in the ﬁnal model of
multivariable analysis and excluded these cases in an
additional sub-analysis in order to reveal possible reverse
causation. Besides these strengths, the current study also
presented some limitations. First, the data presented refer
only to the baseline examination and coffee consumption
was self-reported. Therefore, we were not able to control for
possible variation of coffee intake during the follow-up
period. Second, data regarding the type of coffee and
methods of preparation were not collected. Thus, we can
only assume homogeneous preparation methods within
and between countries, but differences regarding the use of
caffeinated and decaffeinated coffee may still exist. Third, the
study had relatively short follow-up, thus cases are limited,
especially regarding cancer mortality. Fourth, the last
category of exposure included fewer individuals than
others and this could have affected the statistical power.
Nevertheless, for analysis, we preferred to consider this
category as separate due to a different biological effect of
extreme coffee consumption. Finally, the sample was
recruited in urban centres and thus should not be considered
nationally representative.
Conclusion
In conclusion, in our cohort coffee consumption was
associated with decreased risk of all-cause and CVD
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mortality. The healthful effect of coffee seems to rely on
CVD, but additional analyses focused on non-smokers are
needed to further investigate potentially preventive effects
also against cancer.
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